Tag: triple negative breast cancer

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Phase 3 Study Supports Sacituzumab Govitecan + Pembrolizumab as a Potential New Standard of Care in First-line PD-L1+ mTNBC

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

ESMO 2025: First Global Phase I Results of Izalontamab Brengitecan in Patients with Advanced Solid Tumors

A first patients has been dosed in the WIN-B study (NCT06612203)*, a Phase 1b/2, multi-center investigator-initiated trial evaluating the safety and preliminary efficacy of...

Zelenectide pevedotin, comprised of a bicyclic peptide targeting Nectin-4 conjugated via a valine-citrulline cleavable linker to monomethyl auristatin E (MMAE), has demonstrated enhanced anti-tumor activity in triple-negative breast cancer (TNBC-) patients with Nectin-4 gene amplification.

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan + durvalumab (Imfinzi®; AstraZeneca;  Arm 7) showed that the treatment combination demonstrated durable tumor responses without  new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer (mTNBC) with six months additional follow-up from the previous data cut-off.

Results from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients...

This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...